All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
MediCom Oncology Clinical Pearls Podcasts
8 minutes 26 seconds
8 years ago
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
